December 18, 2012
By now the whole country is fully embroiled in the Gun Control debate, spurred by the grisly murder of 27 people, mostly kids, at the Sandy Hook Elementary school last Friday.
Guns might not be the only problem though.
New York Magazine wrote a piece about shooter Adam Lanza’s supposed “aspergers” syndrome as a “red herring” meant to distract from the real problem (guns, of course, the subject goes without mentioning).
Inside the piece though they report Adam Lanza’s uncle said the boy was prescribed Fanapt, a controversial anti-psychotic medicine.
Fanapt was the subject of a Bloomberg report when it passed regulators, after previously getting the “nonapproval” stamp. Why wasn’t it approved, you might ask?
There are many reasons, some of which have to do with competing entities in a competitive market.
The main cited reason for the rejection was that it caused severe heart problems in enough patients to cause a stir.
Maybe more importantly, though, Fanapt is one of a many drugs the FDA pumped out with an ability to exact the opposite desired effect on people: that is, you know, inducing rather than inhibiting psychosis and aggressive behavior.
In fact, Fanapt was dropped by its first producer, picked up by another, initially rejected by the FDA, then later picked up and mass produced. The adverse side-effect is said to be “infrequent,” but still it exists, and can’t be ignored.
The reaction invoked by the drug in some people is reminiscent of the Jeffrey R. MacDonald case, where a Green Beret slaughtered his entire family and then fabricated a story about a marauding troop of “hopped up hippies”.
MacDonald though, had Eskatrol in his system, a weight-loss amphetamine that’s since been banned in part for its side effects of psychotic behavior and aggression.
These drugs are not the only ones that can cause the opposite of their desired effect. Several anti-depressant medications are also restricted to adults, for the depression they inspire in kids rather than eliminate.
This article was posted: Tuesday, December 18, 2012 at 5:17 pm